# Histamine H2-receptor antagonists for decreasing gastrointestinal harms in adults using aspirin: Systematic review and meta-analysis

Andrea C. Tricco, PhD; Abdullah Alateeq, MD;Mariam Tashkandi, MD; Muhammad Mamdani, PharmD; Mohammed Al-Omran, MD, MSc; Sharon E. Straus, MD, MSc.

**Andrea C. Tricco** is a Scientist at the Li Ka Shing Knowledge Institute of St Michael’s Hospital, Toronto, Ontario, Canada. (TriccoA@smh.ca)

**Abdullah Alateeq** was a Medical Intern in the College of Medicine at King Saud University, Riyadh, Saudi Arabia during the conduct of this review. He is now a Cardiology Scholarship Resident at the Prince Salman Heart Center, King Fahad Medical City, Riyadh, Saudi Arabia (aal-ateeq@hotmail.com)

**Mariam Tashkandi** is a research assistant in the Applied Health Research Centre of St. Michael's Hospital, Toronto, Ontario, Canada (mariam.tashkandi@gmail.com)

**Muhammad Mamdani** is the Director of the Applied Health Research Centre and Scientist in the Keenan Research Centre at St. Michael's Hospital. He is also an Associate Professor in the Department of Health Policy, Management and Evaluation, and Leslie Dan Faculty of Pharmacy, at the University of Toronto, Toronto, Ontario, Canada. (MamdaniM@smh.ca)

**Mohammed Al-Omran** is a Scientist in the Keenan research Centre of the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Toronto, Ontario, Canada. His is also an Assistant Professor and KSU Research Chair in Peripheral Vascular Disease in the Department of Surgery at King Saud University, and Staff Surgeon in the Division of Vascular Surgery in King Khalid University Hospital, Riyadh, Saudi Arabia. (malomran@ksu.edu.sa)

**Sharon E. Straus** is the Director of the Knowledge Translation program and Scientist in the Keenan Research Centre of the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Toronto, Ontario, Canada. She is also a Divisional Director of Geriatric Medicine, and Professor in the Department of Medicine and Department of Health Policy Management and Evaluation, at the University of Toronto, Ontario, Canada. (sharon.straus@utoronto.ca)

**Competing interests:** None declared

**Corresponding Author:** Sharon Straus, MD, MSc; St Michael’s Hospital, 30 Bond Street,

Toronto, Ontario M5B 1W8; Telephone: 416-8964-6060, ext 77140, email: sharon.straus@utoronto.ca, fax: 416-864-5805

**Running title:** H2 blockers for decreasing gastrointestinal harms

**Word count:** 282 (abstract), 2,365 (main text), 33 references, 3 tables, 4 figures, 1 appendix.

**Key words:** aspirin, histamine H2-receptor antagonist, dyspepsia, peptic ulcer disease, gastrointestinal bleeding, randomized controlled trial, systematic review, meta-analysis.

**Abstract**

**Background:** It is unclear if H2 blockers prevent gastrointestinal harm across a variety of different harm outcomes for patients taking aspirin over long periods of time.

**Methods:** Electronic databases (e.g., MEDLINE, EMBASE, Cochrane from inception to November 2010) and references of retrieved articles were searched. Randomized controlled trials (RCTs) assessing the efficacy of H2 blockers in reducing gastrointestinal harms (bleeding, ulcers) among adults taking aspirin 2 weeks or longer were included. Study and patient characteristics were abstracted and study quality was appraised using the Cochrane risk of bias tool by two reviewers, independently. Peto odds ratio (OR) meta-analysis and 95% confidence intervals (CIs) were calculated and heterogeneity was assessed using the I2 and χ2 statistics.

**Results:** Seven RCTs (five major publications and two companion reports) including 566 patients (healthy volunteers, arthritis, diabetes, cerebrovascular or cardiovascular disease) met the eligibility criteria. One trial adequately reported allocation concealment (4 scored unclear) and sequence generation (3 scored unclear, 1 scored no). After a median of 8-10 weeks follow-up, H2 blockers were effective in reducing gastrointestinal hemorrhaging (n=2 studies, OR: 0.07, 95% CI: 0.02, 0.23) and peptic ulcers (OR: 0.18, 95% CI: 0.11, 0.29) versus placebo among patients taking aspirin for two weeks or longer. Sub-group analysis found significant results for duodenal ulcers (n=2 studies, OR: 0.15, 95% CI: 0.06, 0.38). One study reported gastric ulcers; hence meta-analysis was not possible. Substantial clinical heterogeneity was noted across the studies, including types of H2 blockers, dosing of aspirin, and underlying conditions and statistical heterogeneity was low to moderate

**Interpretation:** H2 blockers reduced gastrointestinal harm among patients taking aspirin for 2 weeks or longer. Given the large proportion of patients taking long-term aspirin, H2 blockers should be considered.

**Introduction**

Aspirin is one of the most widely used medications in the world [1]. It is recommended for use among high-risk vascular patients due to its antiplatelet effects [2-8]. Surveys of physicians show that more than 85% prescribe aspirin post-myocardial infarction [9,10]. Aspirin also has analgesic, antipyretic, and anti-inflammatory properties. It is often prescribed for patients with migraine [11], acute pain [12], osteoarthritis [13], and post-operative pain[14].

Prolonged use of aspirin is associated with harms including dyspepsia, gastrointestinal mucosal injury, and bleeding, especially among the elderly [15]. Commonly used medications for reducing gastrointestinal harm associated with prolonged aspirin use include prostaglandin analogues, H2-receptor antagonists (H2 blockers), and proton pump inhibitors. It is unclear if H2 blockers prevent gastrointestinal harm across a variety of different harm outcomes for patients taking aspirin over long periods of time. Since H2 blockers are used for treating acid-related gastrointestinal conditions, including dyspepsia, peptic ulcer disease, and gastroesophageal reflux, it might be plausible that they are useful for preventing aspirin-induced gastrointestinal adverse events. We aimed to evaluate the role of concomitant administration of H2 blockers with aspirin in decreasing gastrointestinal harm.

**Methods**

A systematic review protocol was used to guide the methods of our review, based on the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) Statement [16]. A draft version was compiled, circulated to clinicians and systematic review methodologists, and revised as necessary (available upon request).

**Eligibility criteria**

Inclusion criteria were randomized controlled trials (RCTS) and quasi-RCTs of H2 blockers for gastrointestinal harms among adults (aged ≥18 years) using aspirin for at least 2 weeks continuously. Studies were included regardless of the patient’s condition and comorbidities. Only studies published in English were included. The primary outcome was the incidence of clinically relevant bleeding. Secondary outcomes were the incidence of ulcers (peptic ulcers overall and sub-group analysis of duodenal ulcers and gastric ulcers) and incidence of dyspepsia.

**Information sources**

Medical Subject Headings and text words related to H2 blockers (e.g., ranitidine, cimetidine, famotidine) for adults taking aspirin were used to search MEDLINE (OVID interface, 1950 to November 2010), EMBASE (OVID interface, 1980 to November 2010), CINAHL (EBSCOhost interface, 1997 to November 2010), and the Cochrane Central Register of Controlled Trials (Wiley interface, inception to November 2010). The search was supplemented by searching a clinical trial registry (MetaRegister, http://www.controlled-trials.com/mrct/), the reference lists of included studies, the authors’ personal files, and contacting experts in H2 blockers.

**Search**

An experienced information specialist conducted all of the literature searches. The search strategy for the main electronic search (MEDLINE) is presented in the Appendix; details on the other searches are available from the authors on request.

**Study selection**

Two independent reviewers screened the search results for inclusion using a pre-defined relevance criteria form and obtained the full-text of potentially relevant articles and screened them to determine inclusion. Discrepancies at any stage were resolved by discussion or the involvement of a third reviewer. The level of agreement during screening was assessed using a kappa statistic [17]. We determined *a priori* that an acceptable level of agreement would be ≥60% [17].

**Data collection process**

A draft data extraction form was developed, piloted, and modified as necessary. Two reviewers extracted all of the data using the standardized data extraction form, independently. Discrepancies were resolved by discussion or the involvement of a third reviewer. When multiple study publications reported data from the same population (i.e., companion reports) the trial reporting the primary outcome of interest was considered the major publication and the other report(s) was used for supplementary data. If the included study was a cross-over RCT, only data for the first period before the cross-over were abstracted.

**Data items**

The extracted data included study characteristics (e.g., study period, sample size, trial arms, setting), participant characteristics (e.g., population, medical condition, mean age, gender), and results from the primary and secondary outcomes.

**Risk of bias**

The risk of bias in individual studies was assessed using the Cochrane Risk of Bias tool [18]. This tool consists of six items pertaining to sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other sources of bias. Two reviewers assessed study quality independently and discrepancies were resolved by discussion or the involvement of a third reviewer.

**Statistical Analysis**

The studies were plotted in a forest plot to examine heterogeneity visually. Statistical heterogeneity was examined using the I2 and χ2 statistics [19]. Peto odds ratios were calculated, as few patients were included in the meta-analyses [18]. Ninety-five percent confidence intervals were derived based on a normal distribution. All analyses were conducted in Review Manager Version 5 [18].

**Results**

**Study selection**

The literature search yielded 645 citations (i.e., titles and abstracts; Figure 1). From this, 394 citations were excluded because they did not examine H2 blockers, 116 because aspirin was not the comparator, 99 because they were not RCTs, and nine because they did not include adult patients. Twenty-six full-text articles were retrieved and examined for relevance and five RCTs fulfilled the inclusion criteria [20-24] (Figure 1). One RCT [24] had two companion reports [25,26], which were used for supplemental data. Twelve articles were excluded at the full-text level of screening because they examined aspirin use for less than 2 weeks, five because they did not have any relevant outcomes, and two because they were not RCTs. There was moderate agreement between reviewers at level 1 screening (kappa=0.60, 95% CI: 0.41 to 0.72).

**Study and patient characteristics**

All of the included studies were RCTs conducted between 1978 and 2009 in the United States, United Kingdom, and Japan (Table 1). The number of participants ranged from 18 to 404 and the duration of follow-up ranged from 4 weeks to 12 weeks. The types of H2 blockers examined included ranitidine, cimetidine, famotidine, lafutidine, and nizatidine. The aspirin dosage ranged from low (e.g., <325 mg) to high (e.g., >1900 mg).

The patient population varied across the included RCTs (Table 2). Healthy adults were included in one RCT [20], two RCTs included patients with rheumatic diseases [21,23], and one RCT included patients with cardiovascular disease, cerebrovascular disease or diabetes [24]. All of the studies performed pre- and post-aspirin use endoscopy. The results of the pre-aspirin endoscopy were used to determine participant inclusion in several studies; one RCT included patients without mucosal injury [20], two RCTs included patients with ulcers or sores [23,24], and two RCTs excluded patients with ulcers or bleeds from inclusion [20,24]. Only one of the included studies reported the number of years that the patients were taking aspirin, which was at least one month before the trial [23].

**Risk of bias**

One of the included RCTs adequately generated (4 scored unclear) and concealed (3 scored unclear, 1 scored no) allocation (Table 3) [24]. Blinding was adequate in four of the RCTs (1 scored no [22]) and three of the RCTs adequately addressed incomplete outcome data (2 scored no [20,21]. Selective outcome reporting was unclear in four of the RCTs (1 scored no [23]) and most reports were free of other types of bias (1 scored unclear because it was funded by private industry [24]).

**Primary outcome meta-analysis results**

None of the studies reported the incidence of clinically relevant bleeding. However, two studies reported gastrointestinal hemorrhage as confirmed by endoscopy. After median of 8 weeks follow-up, patients who were administered an H2 blocker were significantly less likely to experience gastrointestinal hemorrhage compared with placebo (n=2 studies, odds ratio: 0.07, 95% CI: 0.02, 0.23; Figure 2) [20,24]. This means that patients who only took placebo had 14.2 times the odds of experiencing gastrointestinal hemorrhage compared to patients taking H2 blockers. Both of these studies examined low doses of H2 blockers (≤300 mg/day), yet one examined a low dose of aspirin (325 mg/day) [24] and the other examined a high dose of aspirin (2600 mg/day) [20]. Furthermore, one of the studies included healthy adults [20] and the other included patients with diabetes, cardiovascular disease or cerebrovascular disease [24]. One study excluded mucosal inclusion, ulcers or bleeds [20] and the other study included patients with gastric or duodenal scars or erosions but also excluded patients with ulcers or bleeds [24]. Despite this clinical heterogeneity, statistical heterogeneity was not observed (I2=0%, p-value=0.047 on χ2). We were unable to perform sensitivity analysis to explore the clinical heterogeneity, as only two studies were included in this analysis.

**Secondary outcome meta-analysis results**

After a median of 10 weeks follow-up, H2 blockers were effective in reducing the incidence of peptic ulcers (n=4 studies, odds ratio: 0.18, 95% CI: 0.11, 0.29) (Figure 2) [20-24]. Most of these studies examined low doses of H2 blockers (≤300 mg/day), yet one examined a high dose of H2 blockers (1200 mg/day) [23]. Two studies examined a low dose of aspirin (≤325 mg/day) [22,24] and the others examined high doses of aspirin (2600 mg/day) [20,23]. Furthermore, the patients included ranged from healthy adults [20] to patients with rheumatic disease [23] or those with diabetes, cardiovascular disease or cerebrovascular disease [24]. Moderate statistical heterogeneity was noted (I2=56%), yet it did not reach statistical significance (p-value =0.08 on χ2).

Two of the studies excluded ulcers or bleeds [20,24] and the other two included ulcers or bleeds. A sensitivity analysis was conducted to examine the effects of ulcers or bleeds on the meta-analysis results. The meta-analysis results were unchanged when the analysis was conducted only including the two studies that excluded ulcers (n=2 studies, odds ratio: 0.19, 95% confidence interval: 0.11, 0.33, I2=0%) [20,24], as well as only including the two studies that included ulcers (n=2 studies, odds ratios: 0.15, 95% confidence interval: 0.05, 0.43, I2=85%) [22,23]. The results of the second sensitivity analysis should be interpreted with caution, as significant heterogeneity was observed (p-value=0.01 on χ2) and this is likely because all of the participants in the O’Laughlin et al. study included patients with ulcers [23].

Sub-group analysis indicated that H2 blockers were effective in reducing duodenal ulcers (n=2 studies, RR: 0.15, 95% CI: 0.06, 0.38) versus placebo (Figure 3) [20,24]. The duodenal and peptic ulcer meta-analysis results were not affected by statistical heterogeneity (I2=0%), despite significant clinical heterogeneity. Sensitivity analysis was not conducted, as only two studies were included in this analysis. Only one of the included studies reported gastric ulcers (odds ratio: 0.20, 95% CI: 0.09, 0.47) [24] so sub-group analysis was not possible.

One of the included studies reported the proportion of patients experiencing dyspepsia, yet few patients experienced this outcome (n=4) and this result was not reported per treatment group [21]. None of the other included studies reported data on dyspepsia.

**Harms related to H2 blockers**

Two of the included studies reported adverse events [20,22] and 0 events were observed for patients receiving aspirin plus H2 blockers, as well as those taking aspirin plus placebo.

**Discussion**

Aspirin is one of the most common drugs prescribed to patients and the gastrointestinal harm associated with its prolonged use is well known. A recent systematic review found that 109 major cardiovascular events were prevented for every 10,000 diabetic patients treated with aspirin at the expense of 19 major bleeding events [27]. We found that H2 blockers were effective in reducing gastrointestinal bleeding and peptic ulcers, suggesting that these agents should be considered in routine practice among adults taking aspirin for two weeks or more. One of the included studies reported the proportion of patients experiencing dyspepsia so we were unable to assess this outcome.

Given that aspirin is such a common drug and the adverse effects are well known, it was surprising to note the dearth of studies that were identified on this topic. This could be because most of the research in this area has focused on other agents, such as proton pump inhibitors and misoprostol or on non-steroidal anti-inflammatory drugs (NSAIDs) other than aspirin. Indeed, a recent Cochrane review on a similar topic found double the number of studies evaluating misoprostol versus H2 blockers among patients concurrently taking a variety of NSAIDs [28]. In this Cochrane review, the relative benefits of these agents were unclear and future reviews should examine these differences, perhaps through indirect comparisons meta-analysis, as few head-to-head trials exist. Another issue to take into consideration in future reviews is the cost of H2 blockers, as a recent cost effectiveness analysis found that starting with antacids and H2 blockers was more cost effective than starting with proton pump inhibitors and moving to H2 blockers and antacids [29].

We found that H2 blockers were effective in reducing duodenal ulcers, which is consistent with a recent Cochrane review on a similar topic [28]. Although our review was more focused, we included four more RCTs and an important additional outcome (gastrointestinal bleeding) than the Cochrane review.

We found that many of the included RCTs had small sample sizes and were poorly reported. Furthermore, only one of the included RCTs reported adequately on more than three of the 6 risk of bias items [24], suggesting that our meta-analyses results should be interpreted with caution. Although statistical heterogeneity was not apparent, there was significant clinical heterogeneity across studies. For example, we combined studies regardless of aspirin dose, H2 blockers dose, and patient conditions. We were unable to fully assess these differences via subgroup analysis, as too few studies were included in the meta-analysis. This should be addressed in updates of this systematic review.

Our systematic review is limited because we did not include studies written in languages other than English. Furthermore, although we searched for unpublished material and contacted trial authors for unpublished material, we were unable to identify relevant unpublished material to include. Furthermore, we did not compare H2 blockers with more commonly used medication, such as proton pump inhibitors.

Across all of the included RCTs, the longest duration of follow-up was 12 weeks [24]. Although the prolonged use (i.e., >45 weeks) of H2 blockers has been found to be safe [30], the long-term safety of concurrent aspirin and H2 blocker intake is unclear. Future RCTs should evaluate the efficacy and safety of using these agents concurrently over time.

In conclusion, H2 blockers reduced gastrointestinal harm among patients taking aspirin for 2 weeks or longer. Given the large proportion of patients taking long-term aspirin, H2 blockers should be considered. Future studies should examine the efficacy and safety of long-term use of H2 blockers among patients taking aspirin for greater than 2 weeks duration.

**Author Contributions**

ACT, AA, MM, and SES conceptualized and designed the study. AA, MT, ACT were involved in the acquisition of the data. ACT analyzed the data. ACT, AA, MM, and SES interpreted the data. ACT and AA wrote the first draft and it was revised for intellectual content by all other authors.

**Acknowledgments**This review was conducted as part of a systematic review course taught by Drs Tricco and Straus through the Li Ka Shing Knowledge Institute of St Michael’s Hospital. We thank Laure Perrier for the literature searches and Charlene Soobiah for formatting the paper.

**Funding**

This systematic review was funded, in part, by the King Saud University.

Reference List

1. Gao R, Li X. Risk assessment and aspirin use in Asian and Western populations. *Vasc Health Risk Manag* 2010;6:943-956.

2. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). *Eur Heart J* 2007;28:88-136.

3. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens* 2007;25:1105-1187.

4. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. *Eur Heart J* 2007;28:1598-1660.

5. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Jr., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2007;50:e1-e157.

6. Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. *Circulation* 2007;115:1481-1501.

7. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. *Diabetes Care* 2007;30:162-172.

8. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council. *Stroke* 2006;37:1583-1633.

9. Zaninelli A, Kaufholz C, Schwappach D. Physicians' attitudes toward post-MI aspirin prophylaxis: findings from an online questionnaire in Europe and Latin America. *Postgrad Med* 2009;121:44-53.

10. Zaninelli A, Hu DY, Kaufholz C, Schwappach D. Physicians' attitudes toward post-MI aspirin prophylaxis: findings from an online questionnaire in Asia-Pacific. *Postgrad Med* 2010;122:108-117.

11. Kirthi V, Derry S, Moore RA, McQuay HJ. Aspirin with or without an antiemetic for acute migraine headaches in adults. *Cochrane Database Syst Rev* 2010;CD008041.

12. Edwards JE, Oldman A, Smith L, Collins SL, Carroll D, Wiffen PJ, et al. Single dose oral aspirin for acute pain. *Cochrane Database Syst Rev* 2000;CD002067.

13. Towheed T, Shea B, Wells G, Hochberg M. Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip. *Cochrane Database Syst Rev* 2000; CD000517.

14. Edwards JE, Oldman AD, Smith LA, Carroll D, Wiffen PJ, McQuay HJ, et al. Oral aspirin in postoperative pain: a quantitative systematic review. *Pain* 1999;81:289-297.

15. Selak V, Elley CR, Wells S, Rodgers A, Sharpe N. Aspirin for primary prevention: yes or no? *J Prim Health Care* 2010;2:92-99.

16. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 2009;339:b2535.

17. Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics* 1977;33:159-174.

18. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Edited by Higgins JPT, Green S. The Cochrane Collaboration 2011. [www.cochrane-handbook.org](http://www.cochrane-handbook.org) . (Accessed 2011 Sept 5)

19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002; 21:1539-1558.

20. Berkowitz JM, Rogenes PR, Sharp JT, Warner CW. Ranitidine protects against gastroduodenal mucosal damage associated with chronic aspirin therapy. *Arch Intern Med* 1987;147:2137-2139.

21. Welch RW, Bentch HL, Harris SC. Reduction of aspirin-induced gastrointestinal bleeding with cimetidine. *Gastroenterology* 1978;74:459-463.

22. Nakashima S, Ota S, Arai S, Yoshino K, Inao M, Ishikawa K, et al. Usefulness of anti-ulcer drugs for the prevention and treatment of peptic ulcers induced by low doses of aspirin. *World J Gastroenterol* 2009;15:727-731.

23. O'Laughlin JC, Silvoso GK, Ivey KJ. Resistance to medical therapy of gastric ulcers in rheumatic disease patients taking aspirin: A double-blind study with cimetidine and follow-up. *Dig Dis Sci* 1982;27:976-980.

24. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. *Lancet* 2009;374:119-125.

25. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention for peptic ulcers in users of low- dose aspirin: Placebo-controlled prospective trial (FAMOUS). *Gastroenterology* 2009;136(Suppl 1):A68-A69

26. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers in users of low-dose aspirin: Placebo-contolled trial. *Gut*  2009;58:A36

27. Butalia S, Leung AA, Ghali WA, Rabi DM. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: A systematic review and meta-analysis. *Cardiovasc Diabetol* 2011;10:25.

28. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, et al. Prevention of NSAID-induced gastroduodenal ulcers. *Cochrane Database Syst Rev* 2002;CD002296.

29. van Marrewijk CJ, Mujakovic S, Fransen GA, Numans ME, de Wit NJ, Muris JW, et al. Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): A primary-care-based randomised controlled trial. *Lancet* 2009; 373:215-225.

30. Hegarty JH, Halvorsen LF, Hazenberg BP, Nowak AF, Smith CL, Thomson AB, et al. Prevention of relapse in reflux esophagitis: a placebo controlled study of ranitidine 150 mg bid and 300 mg bid. *Can J Gastroenterol* 1997;11:83-88.

**Figure legends**

Figure 1: Study flow

Figure 2: Gastrointestinal bleeding meta-analysis

Figure 3: Peptic ulcer meta-analysis

Figure 4: Duodenal ulcer meta-analysis

**Table 1: Study characteristics**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Reference** | **First author, year of publication** | **Type of trial** | **Total**  **#**  **patients** | **Setting** | **Duration of trial in weeks (longest duration of FU)** | **Trial arms**  **(dose/day in mg)** |
| [21] | Welch, 1978 | Cross-over RCT\* | 26 | Rheumatology clinic, University of Texas Health Science center at San Antonio, USA | 8 (8) | Cimetidine (1200) + ASA (2600-3900); Placebo + ASA (2600-3900) |
| [23] | O'Laughlin, 1982 | RCT | 18 | Rheumatology clinics and general medicine wards at the Harry S. Truman Memorial Veterans Hospital and the University of Missouri Medical Center, USA | 8 (104) | Cimetidine (1200) + antacids (prn) + ASA (2600); Placebo + antacids (prn) + ASA (2600) |
| [20] | Berkowitz, 1987 | RCT | 50 | Hospital, USA | 4 (4) | Ranitidine (300) + ASA (2600); Placebo + ASA (2600) |
| [22] | Nakashima, 2009 | RCT | 68 | Saitama Medical University Hospital, Japan | 8 (8) | H2 blockers [9 patients taking famotidine (10-40), 2 patients taking lafutidine (20), 2 patients taking nizatidine (300), 1 patient taking ranitidine (75), 1 patient taking cimetidine (100)] + ASA (81-100); Placebo + ASA (81-100) |
| [24] (CRs: [25,26]) | Taha, 2009 | RCT | 404 | Gastroenterology Unit, Crosshouse Hospital, University of Glasgow, Kilmarnock, UK | 12 (12) | Famotidine (40) + ASA (75-325); Placebo + ASA (75-325) |

**Notes:** \* Data from cross-over RCTs were abstracted prior to the groups crossing over to make the data consistent with the other RCTs. **Abbreviations:** ASA aspirin, CRs companion reports, prn *pro re nata* (i.e., as required), RCT randomized controlled trial, UK United Kingdom, USA United States of America.

**Table 2: Patient characteristics**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Reference** | **# patients** | **Medical reason for taking ASA** | **% Male** | **Age in years: mean (SD)** | **Pre-/post-ASA endoscopy?** | **Mucosal inclusion criteria** | **Excluded ulcers or bleeds?** |
| [21] | 26 (22 included in analysis) | RA or degenerative joint disease | NR | NR | Yes | NR | No |
| [23] | 18 (ITT) | Rheumatic disease | NR | NR | Yes | Confirmed gastric ulcer included | No |
| [20] | 50 (43 included in analysis) | None | 100% | Ranitidine 28.5 (SE 2.2), Placebo 26.2 (SE 2.0); Range:18-57 | Yes | No abnormality | Yes |
| [22] | 68 (0 dropouts) | NR | 66.2 | Range: 25-88 | Yes | NR | No |
| [24] (CRs: [25,26]) | 404 (ITT) | Cardiovascular, cerebrovascular, and diabetes | 68.6 | Famotidine 63 (range 36-86), Placebo 63 (range 37-86) Median age: 63 years | Yes | Patients with gastric or duodenal scars or erosions included | Yes (allowed erosions or scars to be included) |

**Abbreviations:** ASA aspirin, NR not reported, RA rheumatoid arthritis, SD standard deviation, SE standard error, ITT intention-to-treat.

**Table 3: Risk of bias results**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Reference** | **Adequate sequence generation?** | **Allocation concealment?** | **Blinding?** | **Incomplete outcome data addressed?** | **Free of selective reporting?** | **Free of other bias?** |
| [21] | Unclear | No | Yes | No | Unclear | Yes |
| [23] | Unclear | Unclear | Yes | No | No | Yes |
| [20] | Unclear | Unclear | Yes | Yes | Unclear | Yes |
| [22] | Unclear | Unclear | No | Yes | Unclear | Yes |
| [24] | Yes | Yes | Yes | Yes | Unclear | Unclear |